60 related articles for article (PubMed ID: 23845281)
1. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
[TBL] [Abstract][Full Text] [Related]
2. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
3. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
4. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
[TBL] [Abstract][Full Text] [Related]
7. Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities.
Hendriks CM; Penning TM; Zang T; Wiemuth D; Gründer S; Sanhueza IA; Schoenebeck F; Bolm C
Bioorg Med Chem Lett; 2015 Oct; 25(20):4437-40. PubMed ID: 26372652
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Park S; Song CS; Lin CL; Jiang S; Osmulski PA; Wang CM; Marck BT; Matsumoto AM; Morrissey C; Gaczynska ME; Chen Y; Mostaghel EA; Chatterjee B
Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31894239
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors.
Kulkarni S; Singh Y; Biharee A; Bhatia N; Monga V; Thareja S
J Biomol Struct Dyn; 2023; 41(22):12668-12685. PubMed ID: 36744535
[TBL] [Abstract][Full Text] [Related]
10. The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 catalyzes the activation of testosterone.
Oestlund I; Snoep J; Schiffer L; Wabitsch M; Arlt W; Storbeck KH
J Steroid Biochem Mol Biol; 2024 Feb; 236():106436. PubMed ID: 38035948
[TBL] [Abstract][Full Text] [Related]
11. Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
Maddeboina K; Jonnalagadda SK; Morsy A; Duan L; Chhonker YS; Murry DJ; Penning TM; Trippier PC
J Med Chem; 2023 Jul; 66(14):9894-9915. PubMed ID: 37428858
[TBL] [Abstract][Full Text] [Related]
12. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
13. Steroid hormone transforming aldo-keto reductases and cancer.
Penning TM; Byrns MC
Ann N Y Acad Sci; 2009 Feb; 1155():33-42. PubMed ID: 19250190
[TBL] [Abstract][Full Text] [Related]
14. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies.
Li M; Zhang L; Yu J; Wang X; Cheng L; Ma Z; Chen X; Wang L; Goh BC
Front Pharmacol; 2024; 15():1378292. PubMed ID: 38523637
[TBL] [Abstract][Full Text] [Related]
15. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
Detlefsen AJ; Mesaros CA; Duan L; Penning TM
Cancer Res Commun; 2023 Sep; 3(9):1888-1898. PubMed ID: 37772993
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure determination, molecular docking, and molecular dynamics of arylal dimedones as potential inhibitors for castrate-resistant prostate cancer.
R C; Kiran KS; Chaithanya MS; M A
Biotechnol Appl Biochem; 2023 Dec; 70(6):1794-1805. PubMed ID: 37279111
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.
Sancéau JY; Maltais R; Zhou M; Lin SX; Poirier D
J Steroid Biochem Mol Biol; 2024 May; ():106544. PubMed ID: 38754521
[TBL] [Abstract][Full Text] [Related]
18. Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader.
Carmona AV; Jonnalagadda S; Case AM; Maddeboina K; Jonnalagadda SK; Dow LF; Duan L; Penning TM; Trippier PC
Commun Chem; 2024 Apr; 7(1):95. PubMed ID: 38684887
[TBL] [Abstract][Full Text] [Related]
19. In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.
Plavša JJ; Řezáčová P; Kugler M; Pachl P; Brynda J; Voburka Z; Ćelić A; Petri ET; Škerlová J
Acta Crystallogr F Struct Biol Commun; 2018 May; 74(Pt 5):300-306. PubMed ID: 29717998
[TBL] [Abstract][Full Text] [Related]
20. Finding New Molecular Targets of Familiar Natural Products Using In Silico Target Prediction.
Mayr F; Möller G; Garscha U; Fischer J; Rodríguez Castaño P; Inderbinen SG; Temml V; Waltenberger B; Schwaiger S; Hartmann RW; Gege C; Martens S; Odermatt A; Pandey AV; Werz O; Adamski J; Stuppner H; Schuster D
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
